What changed: Node-positive and metastatic penile cancer
Every dated change on the records linked to Node-positive and metastatic penile cancer, newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.
September 2026 · 1
2023 · 6
- 2023GuidelineNode-positive and metastatic penile cancerGuideline EAU-ASCO Collaborative Guideline on Penile Cancer 2023: After lymphadenectomy with pelvic nodes or extranodal extension
Adjuvant chemotherapy or chemoradiotherapy, ideally within InPACT because the benefit is unproven.
- 2023GuidelineNode-positive and metastatic penile cancerGuideline EAU-ASCO Collaborative Guideline on Penile Cancer 2023: Bulky or fixed inguinal nodes
Neoadjuvant TIP chemotherapy (paclitaxel, ifosfamide, cisplatin) followed by lymphadenectomy in responders; chemoradiotherapy as an alternative within InPACT.
- 2023GuidelineNode-positive and metastatic penile cancerGuideline EAU-ASCO Collaborative Guideline on Penile Cancer 2023: HPV 16-positive recurrent disease
Trials of HPV-directed vaccines with checkpoint inhibition (TG4001 with avelumab).
- 2023GuidelineNode-positive and metastatic penile cancerGuideline EAU-ASCO Collaborative Guideline on Penile Cancer 2023: Metastatic disease
Platinum-based chemotherapy (TIP, paclitaxel-cisplatin, or with fluorouracil); PD-1 antibodies in trials or later lines (pembrolizumab, cemiplimab).
- 2023GuidelineNode-positive and metastatic penile cancerGuideline EAU-ASCO Collaborative Guideline on Penile Cancer 2023: Positive sentinel node or resectable palpable nodes
Radical inguinal lymphadenectomy; pelvic lymphadenectomy when two or more inguinal nodes are involved or extranodal extension is found.
- 2023MilestoneLymphadenectomy (lymph node dissection)EAU-ASCO guideline codifies node management; HERCULES reports responses to pembrolizumab with chemotherapy
A milestone in how this cancer is treated.